Ampio Pharmaceuticals, Inc. (AMPE)
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
$2,498.00
Mr. Michael A. Martino
9.00
Englewood, CO
May 19, 2011
0.00
$-10.66
1.72
2.36
-1,699.80%
-0.00
0.00
0.00
0.00
2.36
-145.21%
-143.77%
Similar stocks (14)
Monte Rosa Therapeutics, Inc.
GLUE
Candel Therapeutics, Inc.
CADL
Akari Therapeutics, Plc
AKTX
AN2 Therapeutics, Inc.
ANTX
Synlogic, Inc.
SYBX
Pulmatrix, Inc.
PULM
TransCode Therapeutics, Inc.
RNAZ
Sonnet BioTherapeutics Holdings, Inc.
SONN
Galera Therapeutics, Inc.
GRTX
Revelation Biosciences, Inc.
REVB
Phio Pharmaceuticals Corp.
PHIO
Quoin Pharmaceuticals, Ltd.
QNRX
PaxMedica, Inc.
PXMD
eFFECTOR Therapeutics, Inc.
EFTR
Similar stocks (14)
Monte Rosa Therapeutics, Inc.
GLUE
Candel Therapeutics, Inc.
CADL
Akari Therapeutics, Plc
AKTX
AN2 Therapeutics, Inc.
ANTX
Synlogic, Inc.
SYBX
Pulmatrix, Inc.
PULM
TransCode Therapeutics, Inc.
RNAZ
Sonnet BioTherapeutics Holdings, Inc.
SONN
Galera Therapeutics, Inc.
GRTX
Revelation Biosciences, Inc.
REVB
Phio Pharmaceuticals Corp.
PHIO
Quoin Pharmaceuticals, Ltd.
QNRX
PaxMedica, Inc.
PXMD
eFFECTOR Therapeutics, Inc.
EFTR